Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 2/20 | 0.51 |
| ▸ | HPGDS | O60760 | 2/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 8/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 8/20 | 0.48 |
| ▸ | ITGAL | P20701 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22896955 | 0.94 | ITGB2 (0.48) | BBOX1HPGDSERAP2ITGB2ICAM1 | |
| SCHEMBL22896694 | 0.91 | GAA (0.49) | BBOX1HPGDSERAP2ITGB2ICAM1 | |
| SCHEMBL22896953 | 0.90 | ITGB2 (0.49) | BBOX1HPGDSERAP2ITGB2ICAM1 | |
| SCHEMBL22897039 | 0.88 | ITGB2 (0.48) | BBOX1HPGDSERAP2ITGB2ICAM1 | |
| SCHEMBL22896275 | 0.86 | ITGB2 (0.45) | BBOX1HPGDSERAP2ITGB2ICAM1 | |
| SCHEMBL22896846 | 0.84 | CAPN1 (0.49) | BBOX1HPGDSLNPEP | |
| SCHEMBL20028007 | 0.82 | CCKBR (0.41) | — | |
| SCHEMBL22897201 | 0.82 | F10 (0.45) | TACR1CTSL | |
| SCHEMBL21854063 | 0.81 | CAPN1 (0.53) | CTSL | |
| SCHEMBL20028431 | 0.81 | CAPN1 (0.53) | CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | BBOX1 2495/4885HPGDS 1604/4885ERAP2 134/4885 |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | BBOX1 2495/4885HPGDS 1604/4885ERAP2 134/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | BBOX1 2562/4885HPGDS 1339/4885ERAP2 329/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | BBOX1 2495/4885HPGDS 1604/4885ERAP2 134/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | BBOX1 2495/4885HPGDS 1604/4885ERAP2 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.